ERBB2 and breast cancer: Prognostic analysis revealed that kinase fusion positivity is associated with poorer outcomes exclusively in HR+/HER2‒ breast cancer, with no significant prognostic impact observed in other subtypes (Fig. 3a and Supplementary Fig. S3c).